Herantis Pharma Plc ("Herantis") announced today the initiation of a non-invasive CDNF development program to broaden the application of CDNF in Parkinson`s disease and potentially other ...
Cerebral dopamine neurotrophic factor (CDNF) and its close structural relative, mesencephalic astrocyte-derived neurotrophic factor (MANF), are proteins with neurotrophic properties. CDNF protects and ...
Cerebral dopamine neurotrophic factor (CDNF) is an unconventional neurotrophic factor that is a disease-modifying drug candidate for Parkinson’s disease. CDNF has pleiotropic protective effects on ...
Researchers have discovered a novel neurotrophic factor CDNF (Conserved Dopamine Neurotrophic Factor) that was shown to protect and even rescue damaged dopamine neurons in an experimental model of ...
In Parkinson’s disease (PD) dopamine (DA) neurons located in the substantia nigra (SN) degenerate and die. Since all current therapies only treat symptoms, we hope to develop novel disease-modifying ...
The Medicines Agency of Sweden, MPA, has authorized Herantis Pharma Plc`s ("Herantis") first-in-human clinical study of the company`s investigational product CDNF for the treatment of Parkinson`s ...
A research group at the University of Helsinki and its partners have found a promising drug candidate for the treatment of amyotrophic lateral sclerosis (ALS). Cerebral dopamine neurotrophic factor ...
* HERANTIS PHARMA OYJ - TOPLINE ANALYSIS CONFIRMS POSITIVE SAFETY AND TOLERABILITY OF CDNF IN ADVANCED-STAGE PARKINSON'S DISEASE PATIENTS, WITH ENCOURAGING BIOLOGICAL RESPONSES AS MEASURED BY PET ...
Cerebral dopamine neurotrophic factor CDNF is being tested in phase one and two clinical trials in Finland and Sweden. Cerebral dopamine neurotrophic factor (CDNF) is an unconventional neurotrophic ...
Nanoform (Finland), an innovative nanoparticle medicine enabling company, and Herantis Pharma Plc (Finland), focusing on disease modifying therapies for debilitating neurodegenerative diseases based ...
A research group at the University of Helsinki and its partners have found a promising drug candidate for the treatment of amyotrophic lateral sclerosis (ALS). Cerebral dopamine neurotrophic factor ...
A research group at the University of Helsinki and its partners have found a promising drug candidate for the treatment of amyotrophic lateral sclerosis (ALS). Cerebral dopamine neurotrophic factor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results